Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?

Chin Clin Oncol. 2024 Feb;13(1):14. doi: 10.21037/cco-23-66. Epub 2023 Oct 9.

Authors

Benedikt Hoeh¹, Felix K H Chun¹, Philipp Mandel¹

Affiliation

¹ Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.

PMID: 37817509
DOI: 10.21037/cco-23-66

No abstract available

Keywords: ARASENS; PEACE-1; Triplet therapy; doublet therapy; metastatic hormone-sensitive prostate cancer (mHSPC).

MeSH terms

Androgen Antagonists / pharmacology
Androgen Antagonists / therapeutic use
Androgens / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Docetaxel / pharmacology
Docetaxel / therapeutic use
Humans
Male
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Pyrazoles*
Standard of Care

Substances

Docetaxel
Androgen Antagonists
darolutamide
Androgens
Pyrazoles